Thoughts on Astellas’s Strategic Investment in Poseida; Astellas Gains Rights over P-MUC1C-ALLO1 Program; First Patient in P-CD19CD20-ALLO1 Trial to Be Dosed in Early 2024; Gracell Announces Private Investment

On Monday, August 7, Poseida and Astellas announced (press release) a strategic investment to support the advancement of Poseida’s cell therapy assets in solid tumors with Astellas receiving the right of exclusive negotiation and first refusal to license P-MUC1C-ALLO1 (allogeneic MUC1C CAR-T). Additionally, Poseida provided (press release) a business update on its allogeneic CAR-T programs and Gracell reported (press release) up to $150M in private placement financing by a syndicate of premier healthcare investors. Below, Celltelligence provides insights on Astellas’s interest in allogeneic cell therapies, while discussing how Poseida and Gracell could benefit from these investments.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.